<DOC>
	<DOCNO>NCT00997984</DOCNO>
	<brief_summary>The primary purpose assess efficacy daily dose optimize SPD503 ( 1 , 2 , 3 4mg/day ) , dose either morning evening , compare placebo , child ADHD measure change baseline score endpoint ADHD-RS-IV .</brief_summary>
	<brief_title>Tolerability Efficacy AM PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride Children 6-12 With Attention-Deficit/Hyperactivity Disorder ( ADHD ) ( The ADHD Tempo Study )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>612 year old ADHD diagnosis ADHDRSIV minimum score 28 CGIS score &gt; = 4 Current , control uncontrolled , comorbid psychiatric diagnosis Condition illness represent inappropriate risk subject Known history presence structural cardiac abnormality , serious heart rhythm abnormality , syncope , cardiac conduction problem , exerciserelated cardiac event , clinically significant bradycardia ; orthostatic hypotension control uncontrolled hypertension Use prohibit medication CNS effect affect cognitive performance History alcohol substance abuse within 6 month Current use medication affect BP heart rate Significantly overweight Weight le 55 lb Known allergy SPD503 Abnormal urine drug alcohol screen</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>ADHD</keyword>
</DOC>